Search results for " triple-negative breast cancer"

showing 10 items of 10 documents

Parthenolide and DMAPT exert cytotoxic effects on breast cancer stem-like cells by inducing oxidative stress, mitochondrial dysfunction and necrosis

2016

Triple-negative breast cancers (TNBCs) are aggressive forms of breast carcinoma associated with a high rate of recidivism. In this paper, we report the production of mammospheres from three lines of TNBC cells and demonstrate that both parthenolide (PN) and its soluble analog dimethylaminoparthenolide (DMAPT) suppressed this production and induced cytotoxic effects in breast cancer stem-like cells, derived from dissociation of mammospheres. In particular, the drugs exerted a remarkable inhibitory effect on viability of stem-like cells. Such an effect was suppressed by N-acetylcysteine, suggesting a role of reactive oxygen species (ROS) generation in the cytotoxic effect. Instead z-VAD, a ge…

0301 basic medicineCancer ResearchNecrosismedicine.disease_causeCancer -- Treatmentchemistry.chemical_compoundOnium CompoundsMedicineCytotoxic T cellBreast -- CancerMembrane Potential Mitochondrialchemistry.chemical_classificationSuperoxideMitochondrial DNAMitochondriaNeoplastic Stem CellsFemaleOriginal Articlemedicine.symptomOligopeptidesSesquiterpenesCell SurvivalNF-E2-Related Factor 2ImmunologyBreast NeoplasmsReal-Time Polymerase Chain Reaction03 medical and health sciencesCellular and Molecular NeuroscienceDownregulation and upregulationCell Line TumorHumansParthenolideparthenolide cancer stem cell triple-negative breast cancer reactive oxygen species nuclear factor erythroid 2-related factor 2Fluorescent DyesReactive oxygen speciesbusiness.industryAcetophenonesNADPH OxidasesCell BiologyCell nuclei -- AbnormalitiesOxidative Stress030104 developmental biologychemistryApocyninImmunologyCancer researchReactive Oxygen SpeciesbusinessOxidative stressTranscription FactorsCell Death & Disease
researchProduct

NF-κB Is a Potential Molecular Drug Target in Triple-Negative Breast Cancers.

2017

Breast cancer continues to cause significant burden in global health morbidity and mortality. Triple-negative breast cancers (TNBCs) are highly aggressive with poor prognosis and are characterized by lack of expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor (Her-2). TNBCs are often resistant to cytotoxic chemotherapy and pose major difficulty in achieving personalized medicine due to their molecular heterogeneity. There is increasing evidence that the aberrant activation of nuclear factor (NF)-κB signaling is a frequent characteristic of TNBCs. We evaluated the effects of different potential NF-κB inhibitors, such as bisindolylmaleimide I (BI…

0301 basic medicineCurcuminEstrogen receptorTriple Negative Breast NeoplasmsPharmacologydiagnostics drug targets NF-kB signaling personalized medicine triple-negative breast cancerBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerCell Line TumorMG132Progesterone receptorGeneticsmedicineGene silencingHumansPrecision MedicineMolecular BiologyTriple-negative breast cancerbusiness.industryCyclohexanonesNF-kappa BCancermedicine.disease030104 developmental biologychemistry030220 oncology & carcinogenesisBenzamidesProteasome inhibitorCancer researchMolecular MedicineFemalebusinessBiotechnologymedicine.drugSignal TransductionOmics : a journal of integrative biology
researchProduct

Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation

2017

MiR-29 family dysregulation occurs in various cancers including breast cancers. We investigated miR-29b-1 functional role in human triple negative breast cancer (TNBC) the most aggressive breast cancer subtype. We found that miR-29b-1-5p was downregulated in human TNBC tissues and cell lines. To assess whether miR- 29b-1-5p correlated with TNBC regenerative potential, we evaluated cancer stem cell enrichment in our TNBC cell lines, and found that only MDA-MB-231 and BT-20 produced primary, secondary and tertiary mammospheres, which were progressively enriched in OCT4, NANOG and SOX2 stemness genes. MiR-29b-1-5p expression inversely correlated with mammosphere stemness potential, and miR-29b…

0301 basic medicineOncologycancer stem cellsCarcinogenesisCell Cycle ProteinsTriple Negative Breast NeoplasmsMicroRNA 29b0302 clinical medicineCell MovementSettore BIO/10 - BiochimicaCancer stem cells; MiR-29b-1; SPIN1; Triple-negative breast cancer; Wnt/β-catenin and Akt signaling pathwaysMedicineBreastBreast -- CancerTriple-negative breast cancerWnt signaling pathwayMicroRNANanog Homeobox ProteinGene Expression Regulation NeoplasticOncologyWnt/β-catenin and Akt signaling pathway030220 oncology & carcinogenesisMiR-29b-1Wnt/β-catenin and Akt signaling pathwaysNeoplastic Stem Cellstriple-negative breast cancerFemaleMicrotubule-Associated ProteinsSignal TransductionResearch Papermedicine.medical_specialtycancer stem cellPaclitaxelDown-Regulation03 medical and health sciencesBreast cancerSOX2Cancer stem cellInternal medicineCell Line TumormicroRNAHumansNeoplasm InvasivenessCell ProliferationSPIN1business.industrySOXB1 Transcription Factorsmedicine.diseasePhosphoproteinsMolecular medicineAntineoplastic Agents PhytogenicMicroRNAs030104 developmental biologyDrug Resistance NeoplasmbusinessOctamer Transcription Factor-3
researchProduct

New tricyclic systems as photosensitizers towards triple negative breast cancer cells.

2022

AbstractNineteen pyrrolo[1,2-h][1,7]naphthyridinones and pyrido[2,3-c]pyrrolo[1,2-a]azepinones were synthesized as new tricyclic systems in which the pyridine ring is annelated to the 6,7-dihydroindolizin-8(5H)-one and 5,6,7,8-tetrahydro-9H-pyrrole[1,2-a]azepine-9-one moieties to obtain potential photosensitizing agents. They were tested for their photoantiproliferative activity on a triple-negative breast cancer cell line, MDA-MB-231, in the dark and under UVA light (2.0 J/cm2). We demonstrated that their toxicity, only when exposed to light, was primarily due to the generation of reactive oxygen species while their photodegradation products were not responsible for their activity. The mos…

7]naphthyridinonePhotosensitizing AgentsPyrrolo[12-h][17]naphthyridinoneCell DeathMDA-MB-231Organic ChemistryPhototoxic activityTriple Negative Breast NeoplasmsApoptosisPyrido[23-c]pyrrolo[12-a]azepinoneTriple-negative breast cancerPyrrolo[1Drug DiscoveryMolecular MedicineHumans2-h][1Pyrido[23-c]pyrrolo[12-a]azepinoneMDA-MB-231; Photosensitizing agents; Phototoxic activity; Pyrido[23-c]pyrrolo[12-a]azepinone; Pyrrolo[12-h][17]naphthyridinone; Triple-negative breast cancerReactive Oxygen SpeciesArchives of pharmacal research
researchProduct

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast canc…

2021

Different immunohistochemical programmed death-ligand 1 (PD-L1) assays and scorings have been reported to yield variable results in triple-negative breast cancer (TNBC). We compared the analytical concordance and reproducibility of four clinically relevant PD-L1 assays assessing immune cell (IC) score, tumor proportion score (TPS), and combined positive score (CPS) in TNBC. Primary TNBC resection specimens (n = 104) were stained for PD-L1 using VENTANA SP142, VENTANA SP263, DAKO 22C3, and DAKO 28–8. PD-L1 expression was scored according to guidelines on virtual whole slide images by four trained readers. The mean PD-L1 positivity at IC-score ≥1% and CPS ≥1 ranged between 53% and 75% with th…

OncologyCPS combined positive scoreTC tumor cellsICI immune checkpoint inhibitorTriple Negative Breast NeoplasmsB7-H1 AntigenMedicineHER2 human epidermal growth factor receptor 2Triple-negative breast cancerRC254-282ICC intraclass correlation coefficientbiologyNeoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineMSI microsatellite instabilityImmunohistochemistrypCR pathological complete responsePFS progression-free survivalImmunohistochemistryOriginal ArticleIC-ScoreIC immune cellsIHC immunohistochemistryProgrammed deathPD-L1medicine.medical_specialtyConcordanceTNBC triple-negative breast cancerOS overall survivalBreast cancerTriple-negative breast cancerPD-L1Internal medicineTPS tumor proportion scoreBiomarkers TumorHumansProgrammed death-ligand 1Reproducibilitybusiness.industryReproducibility of Resultsmedicine.diseaseITT intention to treatCI confidence intervalPD-L1 programmed death-ligand 1biology.proteinSurgeryCPSbusinessKappaTMB tumor mutational burdenBreast
researchProduct

Management and treatment of triple-negative breast cancer patients from the NEMESI study: An Italian experience

2011

Abstract Aims Triple-negative breast cancers (TNBCs) lack expression of oestrogen, progesterone, and Human Epidermal Growth Factor 2 receptors. The NEMESI study described current Italian treatment practices in patients with operable, early-stage breast cancer (EBC). Patients and methods Retrospective, observational study involving 63 Italian oncology centres. Eligible patients were aged ⩾18 years with EBC (stage I–II) who had undergone surgery, received ⩾1 cycle of adjuvant chemotherapy and/or adjuvant hormonal therapy and attended an oncology centre between 1 January 2008 and 30 June 2008. This subanalysis focused on patients with TNBC. Variables evaluated included: demographic data/clinic…

OncologyCancer ResearchSettore MED/06 - Oncologia MedicaReceptor ErbB-2receptormedicine.medical_treatmentreceptorsGuidelineClinical practicechemotherapyAntineoplastic Combined Chemotherapy ProtocolsestrogenMedicineStage (cooking)Triple-negative breast cancerAdjuvant therapy Clinical practice Guidelines Italy National register Triple-negative breast cancer --------------------------------------------------------------------------------Middle AgedCombined Modality TherapyReceptors EstrogenItalyOncologyChemotherapy AdjuvantHormonal therapyFemaleReceptors Progesteronemedicine.medical_specialtyNational registerBreast NeoplasmsprogesteroneGuidelinesAdjuvant therapyBreast canceradjuvantTriple-negative breast canceradjuvant therapy; clinical practice; guidelines; italy; national register; triple-negative breast cancer; aged; antineoplastic combined chemotherapy protocols; breast neoplasms; chemotherapy adjuvant; combined modality therapy; female; humans; italy; middle aged; radiotherapy adjuvant; receptor erbb-2; receptors estrogen; receptors progesterone; retrospective studiesInternal medicineAdjuvant therapyHumansradiotherapyAgedRetrospective StudiesChemotherapybusiness.industryTriple-negative breast cancer --------------------------------------------------------------------------------medicine.diseaseRadiation therapyAged Antineoplastic Combined Chemotherapy Protocols; therapeutic use Breast NeoplasmsRadiotherapy AdjuvantObservational studybusinesserbb-2
researchProduct

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

2021

Abstract Purpose Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2): TNBC accounts for approximately 20% of newly diagnosed breast cancers and is associated with younger age at diagnosis, greater recurrence risk and shorter survival time. Therapeutic options are very scarce. Aim of the present analysis is to provide further insights into the clinical activity of metronomic chemotherapy (mCHT), in a real-life setting. Methods We used data included in the VICTOR-6 study for the present analysis. VICTOR-6 is an Italian multicentre retrosp…

OncologyCancer Researchmedicine.medical_specialtyReceptor ErbB-2Breast NeoplasmsTriple Negative Breast NeoplasmsVinorelbineCapecitabine; Cyclophosphamide; Methotrexate; Metronomic chemotherapy; Triple-negative breast cancer; Vinorelbine; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cyclophosphamide; Female; Humans; Receptor ErbB-2; Retrospective Studies; Breast Neoplasms; Triple Negative Breast NeoplasmsCapecitabineErbB-2Breast cancerTriple-negative breast cancerRetrospective StudieInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalCyclophosphamideTriple-negative breast cancerCapecitabineRetrospective StudiesAntineoplastic Combined Chemotherapy Protocolbusiness.industryMetronomic chemotherapyVinorelbinemedicine.diseaseClinical TrialMetronomic ChemotherapyMetastatic breast cancerRegimenMethotrexateOncologyFemalebusinessBreast NeoplasmHumanReceptormedicine.drug
researchProduct

Mechanisms of Raf-1 Kinase Inhibitor Protein Dysregulation in Triple-Negative Breast Cancers and Identification of Possible Novel Therapeutic Approac…

2014

Triple-negative breast cancers (TNBCs) are a heterogenous group of breast cancers characterized by poor prognosis because they are not amenable to targeted therapies. We have taken into account that altered expression of Raf-1 kinase inhibitor protein (RKIP), a tumor and metastasis suppressor and a promoter of drug-induced apoptosis, is frequent in TNBCs and may be involved in their aggressive biology. Interestingly, the analysis of the possible mechanisms of RKIP downregulation in TNBCs permits the identification and recapitulation of different possible approaches, including epigenetic modulation, e.g., by DNA demethylating agents or histone deacetylase inhibition, and NF-κB inhibition. Th…

Oncologymedicine.medical_specialtybiologybusiness.industryCyclin-dependent kinase 4Settore MED/06 - Oncologia MedicaInhibitor proteinBiochemistryEpigenetic therapy NF-κB inhibition Raf-1 kinase inhibitor protein triple-negative breast cancersInternal medicineRaf 1 kinaseGeneticsbiology.proteinCancer researchSettore BIO/14 - FarmacologiaMolecular MedicineMedicineIdentification (biology)businessTriple negativeEpigenetic therapyBiotechnology
researchProduct

The GRP94 Inhibitor PU-WS13 Decreases M2-like Macrophages in Murine TNBC Tumors: A Pharmaco-Imaging Study with 99mTc-Tilmanocept SPECT

2021

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancers and is not eligible for hormone and anti-HER2 therapies. Identifying therapeutic targets and associated biomarkers in TNBC is a clinical challenge to improve patients’ outcome and management. High infiltration of CD206+ M2-like macrophages in the tumor microenvironment (TME) indicates poor prognosis and survival in TNBC patients. As we previously showed that membrane expression of GRP94, an endoplasmic reticulum chaperone, was associated with the anti-inflammatory profile of human PBMC-derived M2 macrophages, we hypothesized that intra-tumoral CD206+ M2 macrophages expressing GRP94 may represent innovative…

QH301-705.5GRP94M2-like macrophages03 medical and health sciences0302 clinical medicineBreast cancerIn vivoSpect imagingmedicineBiology (General)Triple-negative breast cancerGRP94; M2-like macrophages; triple-negative breast cancer; PU-WS13; SPECT imaging; biomarker; CD206; Tilmanocept030304 developmental biology0303 health sciencesTumor microenvironmentSPECT imagingbusiness.industryGeneral Medicinemedicine.diseasePU-WS133. Good health030220 oncology & carcinogenesisCancer researchtriple-negative breast cancerBiomarker (medicine)biomarkerbusinessCD8HormoneCells
researchProduct

Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects

2022

Immunotherapy is improving the prognosis and survival of cancer patients, but despite encouraging out-comes in different cancers, the majority of tumors are resistant to it, and the immunotherapy combinations are often accompanied by severe side effects. Here, we show that a periodic fasting-mimicking diet (FMD) can act on the tumor microenvironment and increase the efficacy of immunotherapy (anti-PD-L1 and anti-OX40) against the poorly immunogenic triple-negative breast tumors (TNBCs) by expanding early exhausted effector T cells, switching the cancer metabolism from glycolytic to respiratory, and reducing collagen depo-sition. Furthermore, FMD reduces the occurrence of immune-related adve…

Tumor MicroenvironmentHumansTriple Negative Breast NeoplasmsFastingImmunotherapySettore MED/08 - Anatomia PatologicaGlycolysisnutrition triple-negative breast cancer CP: Cancer CP: Immunology fasting fasting-mimicking diet immunotherapy inflammationB7-H1 AntigenGeneral Biochemistry Genetics and Molecular BiologyCell Reports
researchProduct